Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT

American Journal of Hematology, EarlyView.

Source: American Journal of Hematology - April 28, 2018 Category: Hematology Authors: Norbert ClaudeGorin , MyriamLabopin , DidierBlaise , Pierre ‐YvesDumas , ThomasPabst , Silvia MariaTrisolini , WilliamArcese , MohamedHouhou , MohamadMohty , ArnonNagler Source Type: research